Who is responsible for medical-device development? From startup founder to corporate leadership

Accountability cannot be outsourced

A medical-device leader does not need to personally perform every engineering, regulatory, clinical or quality activity. The responsibility is to ensure that competent people perform the right work, have the authority and resources to do it properly, and create evidence that supports the organisation's decisions.

This remains true when development is outsourced. A design house, software supplier, test laboratory or consultant can perform specialist work, but the legal manufacturer must still understand, approve, integrate and maintain the resulting product and evidence. Delegating an activity is not the same as transferring accountability.

The same responsibility appears differently as organisations grow

The underlying duty is consistent: define the product, organise competent work, control risk, demand objective evidence and support the device throughout its lifecycle. What changes is the management problem.

• A startup founder must create a controlled organisation before speed and funding commitments harden weak assumptions.
• SME management must preserve visibility and accountability as products, people, suppliers and installed-base obligations multiply.
• Corporate leadership must govern portfolios, legal entities, shared capabilities and independent assurance without attempting to make every technical decision.

Startup founders: build the company and the evidence together

The founder's first responsibility is not to produce the most impressive prototype. It is to turn a medical need into a product definition and a development organisation that can make, explain and defend its decisions.

This means identifying the legal manufacturer, intended purpose, users, claims, device boundary, target markets and likely regulatory route early enough to influence the design. It also means funding risk management, verification, validation, clinical evidence, transfer and post-market support—not only the visible engineering work.

• Name owners for quality, regulatory, technical, clinical, risk, verification and lifecycle capabilities.
• Introduce a proportionate quality system while decisions are being made, not shortly before submission.
• Tie investment gates to evidence maturity and unresolved uncertainty, rather than prototype demonstrations alone.
• Retain access to design records, source material, configurations and intellectual property when suppliers are used.
• Ensure the financial runway reaches the next meaningful evidence gate, not merely the next prototype.

SME management: scale without losing control

An established SME often has experienced people, real products and effective informal relationships. Growth exposes the weakness in relying on personal knowledge and unwritten authority. The management task is to preserve practical speed while making responsibilities, decisions and evidence resilient to a larger portfolio, staff changes and regulatory scrutiny.

Management must resist approving more development than its scarce quality, regulatory, clinical, systems, verification and lifecycle functions can support. Released products also continue to consume capacity through complaints, vigilance, cybersecurity, supplier changes, obsolescence and corrective action.

• Assign an accountable owner and deputy for every product and essential capability.
• Use one scalable development framework with justified tailoring rather than project-specific informal methods.
• Bring technical, quality, regulatory, clinical and commercial perspectives together at evidence-based gates.
• Manage critical suppliers without allowing essential product knowledge to migrate outside the company.
• Review new-product commitments and installed-base obligations as one portfolio of work.

Corporate leadership: govern the system

In a larger organisation, governance must make responsibility clearer rather than more distant. Brand ownership, design authority, manufacturing, regulatory registrations and shared services may sit in different entities, but the legal manufacturer's authority and access to evidence must remain real.

Corporate leaders set strategy, investment, accountability, capability and escalation. Competent product teams determine detailed solutions within that system. Effective governance therefore demands evidence and independent challenge without turning senior committees into substitute design teams.

• Make manufacturer, product and decision accountabilities explicit across entities and markets.
• Compare portfolio opportunities using evidence maturity, lifecycle economics and risk—not commercial promise alone.
• Protect independent quality, regulatory, safety, security and technical escalation.
• Standardise essential controls while allowing documented, risk-based tailoring.
• Fund released and legacy products through support, change and eventual retirement.

Why qualified advice is most valuable early

External expertise is often engaged after an audit identifies gaps, a submission is delayed or formal testing exposes a design problem. Consultants can help at that stage, but remediation is normally constrained by decisions already embedded in architecture, contracts, prototypes, claims, records and schedules.

Early advice provides a different kind of value. A suitably qualified consultant can challenge the intended purpose, regulatory assumptions, development plan, capability model, supplier strategy and evidence approach before the organisation commits substantial money or creates evidence it later has to reconstruct.

The most useful engagement is focused and proportionate. It may be a short initial assessment, participation in early decision gates, review of the development and regulatory strategy, or temporary support while internal capability is established. The objective should be to strengthen the organisation's decisions and knowledge—not create permanent dependence on an external expert.

• Before finalising intended purpose, claims, markets or regulatory strategy.
• Before selecting a product architecture or committing to a critical development supplier.
• Before clinical, usability, verification or validation plans constrain the evidence strategy.
• Before investor, board or portfolio milestones are converted into fixed dates and budgets.
• When the organisation cannot identify an experienced internal owner able to challenge and approve the proposed approach.

Choose advice that can withstand challenge

Medical-device consultancy should be selected for relevant product, technology, lifecycle and jurisdictional experience—not confidence alone. Leaders should expect a consultant to make assumptions visible, distinguish requirements from good practice, explain alternatives and trade-offs, and leave a clear record of the reasoning behind recommendations.

A credible adviser will also say where specialist legal, clinical, regulatory or technical input is required. No individual consultant is an expert in every device, market and discipline, and early recognition of that boundary is itself a form of risk control.

A management test

Whatever the size of the organisation, leaders should be able to answer a concise set of questions before authorising greater commitment.

• What medical purpose, users, claims and markets are we committing to?
• Which legal entity is accountable, and does it have genuine control of the product and evidence?
• Do all critical capabilities have competent owners, sufficient capacity and protected escalation?
• What are the largest unresolved clinical, regulatory, technical, supply and lifecycle uncertainties?
• What objective evidence must exist at the next decision gate?
• Are suppliers and consultants transferring knowledge and records into the organisation?
• Could independent advice now prevent a design, evidence or organisational gap that would be costly to correct later?

The leadership conclusion

Founders create the first system of accountability. SME managers make that system scalable. Corporate leaders make it coherent across portfolios and organisational boundaries. At every level, leadership is responsible for the conditions in which safe, effective and supportable medical devices are developed.

Early qualified advice does not remove that responsibility. Used well, it helps leaders exercise it sooner—while the organisation still has the freedom to choose a better route instead of paying later to repair the wrong one.